• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

The Effective Statistician

Enabling statisticians to lead through innovation and excellence - sponsored by PSI

  • Start here!
  • Podcast
  • Free leadership webinar!
  • The Effective Statistician Leadership Program
  • Legal disclosure – about us
  • Datenschutzerklärung – sorry, still in German…
You are here: Home / Knowledge / Getting access for patients to new medications in Germany – the biggest challenges in the HTA process and how to address them: Interview with Carsten Schwenke

Getting access for patients to new medications in Germany – the biggest challenges in the HTA process and how to address them: Interview with Carsten Schwenke

By alexanderhschacht on 2018-11-13 0

Getting access for patients to new medications in Germany – the biggest challenges in the HTA process and how to address them: Interview with Carsten Schwenke
  • share 
  • tweet  
  • share  
  • share 

Today, regulatory approval doesn’t ensure anymore, that patients benefit from new therapies. As statisticians, we also need to ensure access and reimbursement for new treatments in the different markets around the world.

The process to gain this access and reimbursement in Germany comes with very specific challenges. Yet, due to the large impact of Germany on other countries via the complex reference pricing system and the size of the population of Germany, we must understand these topics.

Carsten Schwenke gathered experiences across therapeutic areas with many companies since the start of the new process in Germany. This makes him the most experienced and best connected statistician in the world for this topic.

By listening to this interview, you will

  • get an understanding of the importance of the HTA process in Germany,
  • learn about key processes and stakeholders to reach successful reimbursement,
  • get an overview about common challenges, and
  • learn when and how to address these issues.

In this episode, we cover the following questions:

  • Why do we need a value dossier in Germany, when we launch a new medication?
  • Who are the key stakeholders in the AMNOG process?
  • How does the process look like from a high-level perspective?
  • How is the evidence provided to regulators like EMA different from the analyses provided to GBA?
  • What are the typical problems, many companies struggle with and what are your recommendations to address them?
  • Many people are familiar with the NICE process in England or the ICER in the US. What is different in Germany?
  • Where can people find further information about this process?

Further resources for you about the German system and this episode are:

  • Webinar series from PSI with Carsten Schwenke (video on demand only for PSI members)
  • GBA homepage with submissions
  • IQWiG homepage and the methods paper
  • IQWiG in dialogue,
  • GMDS,
  • biometrical colloquium
  • Carsten Schwenkes homepage – SCOSSIS

About Carsten Schwenke

Never miss an episode of The Effective Statistician

Join your peers and subscribe to get our latest updates by email!

Get the shownotes of our podcast episodes plus tips and tricks to increase your impact at work to boost your career!

Success! Now check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

We won't send you spam. Unsubscribe at any time. Powered by ConvertKit
  • share 
  • tweet  
  • share  
  • share 

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Categories

  • Excellence
  • Innovation
  • Knowledge
  • Leadership

Recent Posts

  • Current trends in data science for pharma – findings from a qualitative survey and what we should do about it!
  • What you can learn about communication of statistics from a statistician working for the BBC
  • What is TransCelerate and how it will impact your work tremendously
  • The rise of R and what role the AIMS SIG plays in it
  • Practical steps to improve your leadership skills

Archives

  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • Start here!
  • Podcast
  • Free leadership webinar!
  • The Effective Statistician Leadership Program
  • Legal disclosure – about us
  • Datenschutzerklärung – sorry, still in German…
The podcast is created in association with PSI!

Copyright © 2019 · Smart Passive Income Pro on Genesis Framework · WordPress · Log in